[{"orgOrder":0,"company":"Hyundai Bioland","sponsor":"Medipost","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase III","graph3":"Hyundai Bioland","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hyundai Bioland \/ Medipost","highestDevelopmentStatusID":"10","companyTruncated":"Hyundai Bioland \/ Medipost"}]

Find Clinical Drug Pipeline Developments & Deals by Hyundai Bioland

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Cartistem (Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell) is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteochondral Lesions of the Talus.

                          Product Name : Cartistem

                          Product Type : Cell & Gene Therapy

                          Upfront Cash : Inapplicable

                          March 17, 2020

                          Lead Product(s) : Allogeneic Umbilical Cord Blood-Derived Mesenchymal Stem Cell

                          Therapeutic Area : Orthopedics/Orthopedic Surgery

                          Highest Development Status : Phase III

                          Sponsor : Medipost

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank